Drug intelligence / Profile preview

bifidobacterium breve mv-16 + lactobacillus rhamnosus hn001

Development stage: Unknown
Lead developer: Morinaga Milk Industry
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is a combination of two probiotic bacterial strains, Bifidobacterium breve MV-16 and Lactobacillus rhamnosus HN001. Both are well-studied probiotics used to support gut health, modulate the immune system, and restore or maintain healthy intestinal microbiota balance. Bifidobacterium breve MV-16 (sometimes also referred to as M-16V) is commonly used in infant formulas and supplements for its role in establishing beneficial gut flora from early life. Lactobacillus rhamnosus HN001 has demonstrated benefits in reducing allergic responses, supporting immune function, and improving outcomes in various gastrointestinal disorders. The combination is typically administered orally as a dietary supplement or functional food ingredient for infants, children, or adults to promote digestive health and immunity[3][5].

Other names: 短双歧杆菌MV-16 + 鼠李糖乳杆菌HN001

Beyond the preview

Go deeper on bifidobacterium breve mv-16 + lactobacillus rhamnosus hn001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium breve mv-16 + lactobacillus rhamnosus hn001.

Explore the full profile